Randall White, CEO, Educational Development Corporation (Nasdaq:EDUC) announced record net revenues for the fiscal third quarter and the nine months ended November 30, 2014. For the nine months ended November 30, 2014, EDC reports record net revenue of $24,923,000, a 23% increase of $4,715,400 when compared to $20,207,600 for the same period in the previous year and net earnings of $762,200 compared to $670,800. On Thursday shares of Educational Development Corporation (NASDAQ:EDUC) closed at $4.82. Company’s sales growth for last 5 years was -2.40%.
Beazer Homes USA, Inc. (NYSE:BZH) has scheduled the release of its financial results for the quarter ended December 31, 2014 on Friday, January 30, 2015 before the open of the market. The Company will hold a conference call on the same day at 9:30 AM ET to discuss the result Beazer Homes USA Inc. (NYSE:BZH) in last trading activity fell -9.30% to close at $16.77. Company weekly performance is -13.69% while its quarterly performance stands at -0.83%. Beazer Homes USA Inc. (NYSE:BZH) is -30.07% away from its 52 week high.
Drug store operator, Rite Aid Corporation (NYSE:RAD) remains focused on increasing return on investment by persistently enhancing its pharmacy and clinical services through the Rite Aid Health Alliance and its Wellness+ customer loyalty program. On Thursday shares of Rite Aid Corporation (NYSE:RAD) closed at $7.34. Company’s sales growth for last 5 years was -0.60% and EPS growth for next 5 years is recorded as 39.71%.
The short ratio of Lubys, Inc. (NYSE:LUB) is 7.13. On a monthly basis, the short interest has registered a change of -0.72%. The shares shorted this month are equal to 0.003 times the outstanding shares. The short interest has confirmed a change of -20.07% in the past 3 months. Luby’s, Inc. (NYSE:LUB) has 14.30% insider ownership while its institutional ownership stands at 43.40%. In last trading activity company’s stock closed at $4.51.
Merck & Co., Inc. (NASDAQ:MRK) announced Tuesday that it will collaborate with Moderna Therapeutics, a pioneer in messenger RNA (mRNA)-based therapies, to develop vaccines and treatments against viral diseases using the company’s novel mRNA technology. On Thursday shares of Merck & Co. Inc. (NYSE:MRK) closed at $61.88. Company’s sales growth for last 5 years was 13.00% and EPS growth for next 5 years is recorded as 6.70%.